Methods for producing viloxazine salts and novel polymorphs thereof
Provided here are methods of manufacture of viloxazine and its various salts, as well as viloxazine-related compounds, such as novel intermediate reaction products and polymorphs thereof. In particular, the methods provide a substantially pure API of viloxazine HCl while avoiding undesirable impurities. The methods further provide for separating, identifying, and characterizing novel polymorphs of viloxazine. Further provided are methods for synthesis and identification and characterization of novel intermediates of viloxazine, as well as for some important metabolites and precursors of metabolites of viloxazine.
1. A substantially pure viloxazine hydrochloride polymorph Form A, wherein said Form A has an X-ray powder diffraction spectrum radiated by Cu-Kα having peaks at diffraction angle degrees 2θ of 8.88°, 16.60°, 17.68°, 18.52°, 19.80°, 24.80°, 26.60°, 28.32°, 29.32°, 29.92°, and 30.48°.
2. The substantially pure viloxazine hydrochloride polymorph Form A of claim 1 , wherein said Form A has an X-ray powder diffraction spectrum illustrated in FIG. 6 , and wherein said Form A has the Raman infrared spectrum illustrated in FIG. 9 , and wherein said Form A has the differential scanning calorimetry (DSC) melting point of 188° C.
3. A substantially pure viloxazine hydrochloride polymorph Form B, wherein said Form B has an X-ray powder diffraction spectrum radiated by Cu-Kα having peaks at diffraction angle degrees 2θ of 8.84°, 16.64°, 17.64°, 18.56°, 19.68°, 21.72°, 26.52°, and 27.44°.
4. The substantially pure viloxazine hydrochloride polymorph Form B of claim 3 , wherein said Form B has the X-ray powder diffraction spectrum illustrated in FIG. 7 , and wherein said Form B has the Raman infrared spectrum illustrated in FIG. 10 , and wherein said Form B has the differential scanning calorimetry (DSC) melting point of 186° C.
5. An oral pharmaceutical composition comprising a pharmaceutically acceptable carrier and the viloxazine hydrochloride polymorph Form A of claim 1 .
6. An oral pharmaceutical composition comprising a pharmaceutically acceptable carrier and the viloxazine hydrochloride polymorph Form B of claim 3 .